Welcome to our dedicated page for Veralto SEC filings (Ticker: VLTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Veralto's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Veralto's regulatory disclosures and financial reporting.
Veralto Corporation reported second quarter 2026 results with sales of $1,474 million, up 7.6% year-over-year, and non-GAAP core sales growth of 4.2%. GAAP net earnings were $241 million, or $0.98 per diluted share, while adjusted net earnings were $274 million, or $1.11 per diluted share, including about $0.05 per share of benefit from IEEPA tariff recoveries.
Operating profit margin was 21.4%, or 24.6% on an adjusted basis. Water Quality delivered 5.7% core sales growth and Product Quality and Innovation 2.0%. Veralto generated $340 million of operating cash flow and $328 million of free cash flow, supported by recent bolt-on acquisitions and share repurchases.
Management guides third quarter 2026 non-GAAP core sales growth to 4.0%–5.0% with adjusted EPS of $1.06–$1.09. For full year 2026, guidance was raised to core sales growth of 4.0%–4.5% and adjusted EPS of $4.35–$4.43, implying 12%–14% year-over-year growth and free cash flow conversion above 100% of GAAP net earnings.
Veralto President and CEO Jennifer Honeycutt exercised 7,097 employee stock options at $28.76 per share on July 17, 2026, receiving 7,097 common shares and selling 7,097 shares at $95.00 per share under a Rule 10b5-1 trading plan, leaving 14,195 options outstanding.
Veralto Corp reported equity awards to director John T. Schwieters on 2026-07-15. He received 1,009 shares of Common Stock, described in a footnote as restricted stock units that vest on the earlier of the first anniversary of the grant date or the next annual shareholder meeting, with underlying shares issued only after specific retirement or death-related timing conditions.
On the same date he was also granted 3,553 Director Stock Options to buy Common Stock at an exercise price of $91.00 per share, which the company states are fully vested as of the grant date and expire on 2036-07-15. After these awards, direct holdings reported are 6,498 shares of Common Stock and 9,413 stock options.
Veralto Corp director Thomas Williams received equity compensation on 2026-07-15. He was granted 1009.0000 restricted stock units tied to common stock, which vest by the next annual shareholder meeting and are issued only after his board service ends. He also received 3553.0000 fully vested director stock options with an exercise price of 91.0000 per share expiring on 2036-07-15, bringing his holdings to 3380.0000 common shares and 9413.0000 options.
Wallis-Lage Cindy L. reported acquisition or exercise transactions in this Form 4 filing.
Veralto Corp director Cindy L. Wallis-Lage received equity awards. She was granted 1,009 restricted stock units that vest on the earlier of the first anniversary of the grant or the next annual shareholders meeting, with shares issued only after board retirement or death. She also received 3,553 fully vested director stock options to buy common shares at $91.00 per share, expiring in 2036, bringing her holdings to 3,380 common shares and 9,413 options held directly.
Veralto Corp director Vijay P. Sankaran reported equity awards. On 2026-07-15 he received 1009.0000 restricted stock units that vest on the earlier of one year or the next annual shareholder meeting, with share delivery deferred until death or several months after board retirement. He was also granted 3553.0000 director stock options for common stock at an exercise price of $91.0000 per share, expiring on 2036-07-15, bringing his direct holdings to 2669.0000 common shares and 7823.0000 options.
Veralto director Heath A. Mitts received equity awards on 2026-07-15, including 1,009 restricted stock units that vest by the earlier of the first anniversary or the next shareholder meeting, with shares issued upon the earlier of his death or the first date of the seventh month after board retirement. He also received 3,553 fully vested director stock options with a $91.00 exercise price expiring on 2036-07-15, bringing his direct holdings to 3,500 common shares and 9,413 options.
Veralto director Walter G. Lohr received equity compensation on July 15, 2026, including 1,009 restricted stock units and 3,553 director stock options. The RSUs vest on the earlier of one year or the next shareholder meeting, with shares delivered after board service ends, while the options are fully vested, carry a $91 exercise price, and expire in 2036. Following these awards he holds 3,380 common shares and 9,413 options directly.
Veralto Corp director William King received equity awards on 2026-07-15. He acquired 1,009 shares of common stock through a grant of restricted stock units that vest on the earlier of the first anniversary of the grant or the next annual shareholder meeting, with shares issued after he leaves the board.
He also received 3,553 director stock options for common stock at an exercise price of $91.00 per share, fully vested at grant and expiring on 2036-07-15. Following these awards he directly holds 9,557 common shares and 9,413 director stock options.
Veralto Corp director Shyam Kambeyanda received equity compensation consisting of 1,099 restricted stock units tied to common stock and 3,553 director stock options with a $91.00 exercise price.
The RSUs vest on the earlier of the first anniversary of the grant date or immediately before the next annual shareholders’ meeting, while the underlying shares are issued only upon the earlier of the director’s death or seven months after retirement from the Board. The options are fully vested as of the grant date and expire on July 15, 2036. Following these grants, Kambeyanda holds 3,470 common shares and 9,413 stock options.